Join us for a live webinar December 3! This program will explore the impact of MDD and the challenges people may face with the disease, including residual symptoms despite antidepressant treatment. We shed light on why adjunctive treatment with an atypical antipsychotic may be considered for these patients and how the patient’s symptom profile can help shape their treatment plan. The efficacy and safety of an atypical antipsychotic treatment option are examined to understand its use as an adjunctive therapy with an antidepressant for the treatment of MDD. Click the link to learn more and register!